Additional file 1 of Comprehensive cross-sectional and longitudinal comparisons of plasma glial fibrillary acidic protein and neurofilament light across FTD spectrum disorders

Supplementary Material 1: Table S1: Summary of relatedness when considering each phenotype group separately. Table S2: Summary of relatedness in each phenotype group in comparison to controls. Table S3: Summary of relatedness in each phenotype group in comparison to the presymptomatic group. Table S4: Breakdown of baseline and longitudinal biomarker measures and rates of their change in phenotype groups. Table S5: Correlations between baseline GFAP and baseline NfL. Table S6: Associations of baseline biomarkers with age, sex, symptom duration, and BMI in phenotype groups – unadjusted analysis. Table S7: Associations of baseline biomarkers with age, sex, symptom duration, and BMI in phenotype groups – adjusted analysis. Table S8: Comparisons of baseline biomarkers between controls or presymptomatic mutation carriers and phenotype groups – unadjusted analysis. Table S9: Comparisons of baseline biomarkers between controls or presymptomatic mutation carriers and phenotype groups – adjusted analysis. Table S10: Baseline biomarker comparisons between asymptomatic groups and symptomatic groups stratified by symptom duration – unadjusted analysis. Table S11: Baseline biomarker comparisons between asymptomatic groups and symptomatic groups stratified by symptom duration – adjusted analysis. Table S12: Comparisons of baseline GFAP and NfL concentration between disease groups. Table S13: AUC values from models including both biomarkers when comparing asymptomatic groups to phenotype groups. Table S14: Comparisons of baseline biomarkers between asymptomatic groups and mildly impaired phenotype groups – unadjusted analysis. Table S15: Comparisons of baseline biomarkers between asymptomatic groups and mildly impaired phenotype groups – adjusted analysis. Table S16: Comparison of baseline biomarkers or their rates of change between controls and phenoconverters or non-converters. Table S17: AUC values from models including both biomarkers when comparing controls to phenoconverters or non-converters. Table S18: Comparison of baseline biomarkers or their rates of change by mutation status in asymptomatic groups. Table S19: Comparison of rate of change in GFAP and NfL concentrations between controls and phenotype groups. Table S20: Characteristics of disease severity indicators according to disease group. Table S21: Associations of baseline GFAP with baseline disease indicators in FTD syndromes and MBCI – unadjusted analysis. Table S22: Associations of baseline GFAP with baseline disease indicators in FTD syndromes and MBCI – adjusted analysis. Table S23: Associations of baseline NfL with baseline disease indicators in FTD syndromes and MBCI – unadjusted analysis. Table S24: Associations of baseline NfL with baseline disease indicators in FTD syndromes and MBCI – adjusted analysis. Table S25: Associations of baseline biomarkers with rates of disease indicator change in all FTD syndromes combined. Table S26: Associations of baseline GFAP and NfL with survival after symptom onset. Table S27: Comparisons of baseline biomarkers or their ratio by mutation status in all FTD syndromes combined. Table S28: Comparisons of baseline biomarkers or their ratio among mutation groups in all FTD syndromes combined. Table S29: Differences in baseline biomarkers or their ratio between FTLD-tau or FTLD-TDP pathology in FTD syndromes